The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis

Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e463-e466. doi: 10.1016/j.clml.2022.01.003. Epub 2022 Jan 8.

Authors

Douglas Tremblay¹, Lara Cavalli², Oumar Sy², Shelonitda Rose², John Mascarenhas³

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: douglas.tremblay@mssm.edu.
² Bristol Myers Squibb, Princeton, NJ.
³ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

PMID: 35120852
DOI: 10.1016/j.clml.2022.01.003

No abstract available

Keywords: JAKARTA; JAKARTA2; Metabolic effects; Ruxolitinib; Weight gain.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Janus Kinase 1
Janus Kinase 2
Primary Myelofibrosis* / drug therapy
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Pyrrolidines
Sulfonamides

Substances

Protein Kinase Inhibitors
Pyrrolidines
Sulfonamides
fedratinib
Janus Kinase 1
Janus Kinase 2